Anti-proteolytic activity of Ganoderma lucidum methanol extract against Pseudomonas aeruginosa
DOI:
https://doi.org/10.3855/jidc.6929Keywords:
Ganoderma lucidum, Pseudomonas aeruginosa, multidrug resistance, virulence factor, proteaseAbstract
Introduction: Protease enzyme is considered one of the most serious virulence factors produced by extended-spectrum β-lactamase-producing and multidrug-resistant Pseudomonas aeruginosa (ESβLMDRPA) clinical isolates.
Methodology: The antibacterial activity of methanol extract of Ganoderma lucidum fruiting bodies was tested against a protease-producing ESβLMDRPA clinical isolate, showing its mode of action.
Results: The extract showed high antibacterial activity. Its effect on purified protease indicated a reversible non-competitive protease inhibition (kis= 0.45 mg/mL).
Conclusions: The G. lucidum extract could be a promising anti-proteolytic active against ESβLMDRPA. It may form a primary platform for further phytochemical studies and development of new drugs for therapy of skin burn infections.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).